Selective serotonin uptake inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 2: | Line 2: | ||
In [[medicine]], '''selective serotonin uptake inhibitors''' (SSRI) are [[second-generation antidepressant]]s that potentiate the effect of [[serotonin]] by blocking its uptake from the synaptic cleft. These were the initial subgroup of the second generation, demonstrating generally improved side effects over the first-generation [[tricyclic antidepressant]]s and [[monoamine oxidase inhibitor]]s. | In [[medicine]], '''selective serotonin uptake inhibitors''' (SSRI) are [[second-generation antidepressant]]s that potentiate the effect of [[serotonin]] by blocking its uptake from the synaptic cleft. These were the initial subgroup of the second generation, demonstrating generally improved side effects over the first-generation [[tricyclic antidepressant]]s and [[monoamine oxidase inhibitor]]s. | ||
While SSRIs remain the group most often prescribed, both clinical response and side effects vary with individual patients. An atypical second-generation drug such as [[venlafaxine]] may induce faster and more reliable relief of depression, but also may have more side effects. | While SSRIs remain the group most often prescribed, both clinical response and side effects vary with individual patients. An atypical second-generation drug such as [[venlafaxine]] may induce faster and more reliable relief of depression, but also may have more side effects.<ref>{{citation | ||
| journal = Br. J. Psychiatry | |||
| year = 2001 | |||
| url = http://www.hawaii.edu/hivandaids/Remission%20Rates%20During%20Treatment%20With%20Venlafaxine%20Or%20Selective%20Serotonin%20Reuptake%20Inhibitors.pdf | |||
| author = Thase ME; Entsuah R; Rudolph RL | |||
| title = Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors | |||
}}</ref> | |||
==Examples== | ==Examples== | ||
Revision as of 21:28, 21 August 2010
In medicine, selective serotonin uptake inhibitors (SSRI) are second-generation antidepressants that potentiate the effect of serotonin by blocking its uptake from the synaptic cleft. These were the initial subgroup of the second generation, demonstrating generally improved side effects over the first-generation tricyclic antidepressants and monoamine oxidase inhibitors.
While SSRIs remain the group most often prescribed, both clinical response and side effects vary with individual patients. An atypical second-generation drug such as venlafaxine may induce faster and more reliable relief of depression, but also may have more side effects.[1]
Examples
- Citalopram (generic). Can be combined with bupropion.
- Duloxetine. Inhibits cytochrome P-450 CYP2D6.
- Fluoxetine (generic). Inhibits cytochrome P-450 CYP2D6.
- Paroxetine (generic). Inhibits cytochrome P-450 CYP2D6. May increase death from breast cancer among women taking tamoxifen due to inhibiting metabolism of tamoxifen to itc active metabolite by cytochrome P-450 CYP2D6.[2]
- Sertraline (generic)
References
- ↑ Thase ME; Entsuah R; Rudolph RL (2001), "Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors", Br. J. Psychiatry
- ↑ Kelly, Catherine M; David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat (2010-02-08). "Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study". BMJ 340 (feb08_1): c693. DOI:10.1136/bmj.c693. Retrieved on 2010-02-10. Research Blogging.